{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:03:22Z","timestamp":1793963002576,"version":"4.8.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006280","name":"Ministerio de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.critrevonc.2021.103305","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T18:44:34Z","timestamp":1616265874000},"page":"103305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-6595","authenticated-orcid":false,"given":"Yi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengrui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-8238","authenticated-orcid":false,"given":"Wenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-8192","authenticated-orcid":false,"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103305_bib0005","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1556-0864(16)30246-5","article-title":"136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J. Comput. Graph. Stat."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0020","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1183\/13993003.02358-2014","article-title":"Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504","volume":"46","author":"Cadranel","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0025","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0030","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/JTO.0b013e3181dc39cd","article-title":"Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia","volume":"5","author":"Chang","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0035","first-page":"137","article-title":"A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer","author":"Cheng","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0050","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2007.15.0672","article-title":"Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study","volume":"26","author":"Crin\u00f2","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.cad.0000203381.99490.ab","article-title":"Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer","volume":"17","author":"Cufer","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0060","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0065","series-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2014"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","article-title":"Targeting EGFR in lung cancer: current standards and developments","volume":"78","author":"D\u00edaz-Serrano","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0075","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0085","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(13)70310-3","article-title":"Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial","volume":"14","author":"Garassino","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0095","first-page":"CD010383","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","author":"Greenhalgh","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(14)70162-7","article-title":"Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial","volume":"15","author":"Gregorc","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0105","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0110","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ijc.30806","article-title":"Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial","volume":"141","author":"Han","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0115","first-page":"JCO2003570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0125","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0130","article-title":"Cochrane Handbook for systematic reviews of interventions version 6.0 (updated July 2019)","author":"Higgins","year":"2019","journal-title":"Cochrane"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0155","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/cncr.28132","article-title":"Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study","volume":"119","author":"Karampeazis","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0160","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2013.52.4694","article-title":"Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)","volume":"32","author":"Kawaguchi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0165","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JTO.0b013e31824cc66c","article-title":"Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB\/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy","volume":"7","author":"Kelly","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0170","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2011.05.022","article-title":"Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy","volume":"75","author":"Kim","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4143\/crt.2014.307","article-title":"Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non-small cell lung cancer","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cct.2006.10.012","article-title":"Clinical trials and the response rate illusion","volume":"28","author":"Kirsch","year":"2007","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0190","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2010.08.012","article-title":"Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity","volume":"70","author":"Ku","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0200","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0210","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-09-1903","article-title":"Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy","volume":"16","author":"Lee","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0215","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-11-2582","article-title":"High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma","volume":"18","author":"Lee","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2018.12.001","article-title":"Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"134","author":"Li","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/1120009X.2018.1516269","article-title":"Fatigue with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"30","author":"Li","year":"2018","journal-title":"J. Chemother."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0230","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/cncr.28591","article-title":"A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma","volume":"120","author":"Li","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0235","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"Lilenbaum","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0240","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0245","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","article-title":"The BUGS project: evolution, critique and future directions","volume":"28","author":"Lunn","year":"2009","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0250","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0255","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer","volume":"26","author":"Maruyama","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0265","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.lungcan.2010.03.003","article-title":"Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)","volume":"70","author":"Mor\u00e8re","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0280","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0285","series-title":"Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. Version 3","author":"NCCN","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0290","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0295","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0305","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0310","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1200\/JCO.2011.40.9433","article-title":"Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer","volume":"30","author":"Ramalingam","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0315","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S1470-2045(14)70452-8","article-title":"Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial","volume":"15","author":"Ramalingam","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0325","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0330","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jtho.2019.03.022","article-title":"Advanced-stage non-small cell lung cancer: advances in thoracic oncology 2018","volume":"14","author":"Remon","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0335","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0340","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.critrevonc.2017.07.003","article-title":"Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going","volume":"117","author":"Russo","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0350","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.12.011","article-title":"Current perspective: osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring","volume":"91","author":"Schiefer","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0365","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0375","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0380","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0385","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.lungcan.2013.11.016","article-title":"Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials","volume":"83","author":"Shi","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0390","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0395","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0400","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/07357907.2019.1634089","article-title":"Skin toxicities with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"37","author":"Sun","year":"2019","journal-title":"Cancer Invest."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0405","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1002\/cncr.27630","article-title":"Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial","volume":"118","author":"Sun","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0410","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/096228020101000404","article-title":"Bayesian methods in meta-analysis and evidence synthesis","volume":"10","author":"Sutton","year":"2001","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0415","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","volume":"88","author":"Takeda","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0420","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L","volume":"34","author":"Urata","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0430","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0435","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0440","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0445","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.2016.456","article-title":"A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations","volume":"116","author":"Yang","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0450","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0455","first-page":"82","article-title":"Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer","volume":"4","author":"Zhai","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0460","doi-asserted-by":"crossref","first-page":"l5460","DOI":"10.1136\/bmj.l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103305_bib0465","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0470","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103305_bib0475","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/annonc\/mdu463","article-title":"Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial","volume":"25","author":"Zhou","year":"2014","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:42:21Z","timestamp":1760902941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":95,"alternative-id":["S1040842821000937"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103305","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103305"}}